Karine Le Malicot

机构：Inserm, Fédération Francophone de Cancérologie Digestive · ORCID：0000-0002-3226-8525

发表论文 203 篇 · 总被引 3462 次 · h-index 30

代表论文

• Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability (2023 · JAMA Oncology · 被引 49)
• LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD (2023 · Annals of Oncology · 被引 29)
• TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 28)
• Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial (2024 · Gastroenterology · 被引 15)
• FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2024 · JAMA Oncology · 被引 14)
• Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma (2025 · Communications Medicine · 被引 13)